Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
  • References (0)
  • Citations (0)
Published on Mar 1, 2019in The Lancet Diabetes & Endocrinology 24.54
Inge B. Halberg1
Estimated H-index: 1
(Novo Nordisk),
Karsten Lyby5
Estimated H-index: 5
(Novo Nordisk)
+ 3 AuthorsLeona Plum-Mörschel5
Estimated H-index: 5
Summary Background Oral insulin 338 (I338) is a long-acting, basal insulin analogue formulated in a tablet with the absorption-enhancer sodium caprate. We investigated the efficacy and safety of I338 versus subcutaneous insulin glargine (IGlar) in patients with type 2 diabetes. Methods This was a phase 2, 8-week, randomised, double-blind, double-dummy, active-controlled, parallel trial completed at two research institutes in Germany. Insulin-naive adult patients with type 2 diabetes, inadequatel...
Published on Mar 1, 2018in Diabetes, Obesity and Metabolism 6.13
David Russell-Jones39
Estimated H-index: 39
(Royal Surrey County Hospital),
Frans Pouwer42
Estimated H-index: 42
(University of Southern Denmark),
Kamlesh Khunti64
Estimated H-index: 64
(University of Leicester)
Poor glycaemic control in type 2 diabetes (T2D) is a global problem despite the availability of numerous glucose-lowering therapies and clear guidelines for T2D management. Tackling clinical or therapeutic inertia, where the person with diabetes and/or their healthcare providers do not intensify treatment regimens despite this being appropriate, is key to improving patients’ long-term outcomes. This gap between best practice and current level of care is most pronounced when considering insulin r...
Published on Oct 17, 2017in JAMA 51.27
Melanie J. Davies66
Estimated H-index: 66
(University of Leicester),
Thomas R. Pieber61
Estimated H-index: 61
(Medical University of Graz)
+ 3 AuthorsJulio Rosenstock112
Estimated H-index: 112
Importance Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the treatment of type 2 diabetes and are all currently available as an injection. Objectives To compare the effects of oral semaglutide with placebo (primary) and open-label subcutaneous semaglutide (secondary) on glycemic control in patients with type 2 diabetes. Design, Setting, and Patients Phase 2, randomized, parallel-group, dosage-finding, 26-week trial with 5-week follow-up at 100 sites (hospital clin...
Published on Jul 1, 2017in Nature Reviews Endocrinology 24.65
Chantal Mathieu78
Estimated H-index: 78
Pieter Gillard14
Estimated H-index: 14
Katrien Benhalima12
Estimated H-index: 12
Insulin treatment has advanced considerably since the discovery of insulin. In this Review, Chantal Mathieu and colleagues discuss the established and novel insulin analogues for the treatment of type 1 diabetes mellitus and consider future developments.
Published on Apr 1, 2016in Diabetes, Obesity and Metabolism 6.13
Kamlesh Khunti64
Estimated H-index: 64
(University of Leicester),
A. Nikolajsen1
Estimated H-index: 1
(Novo Nordisk)
+ 3 AuthorsSanjoy K. Paul26
Estimated H-index: 26
(QIMR: QIMR Berghofer Medical Research Institute)
Aim To investigate whether clinical inertia, the failure to intensify treatment regimens when required, exists in people with type 2 diabetes treated with basal insulin. Methods This was a retrospective cohort study involving patients with type 2 diabetes in the UK Clinical Practice Research Datalink database between January 2004 and December 2011, with follow-up until December 2013. Results A total of 11 696 patients were included in the analysis. Among all patients, 36.5% had their treatment i...
Published on Feb 1, 2016in Journal of Endocrinological Investigation
Vajihe Akbari8
Estimated H-index: 8
(IUMS: Isfahan University of Medical Sciences),
Fatemeh Hendijani5
Estimated H-index: 5
(IUMS: Isfahan University of Medical Sciences)
+ 4 AuthorsS.A. Mostafavi2
Estimated H-index: 2
(IUMS: Isfahan University of Medical Sciences)
Introduction A systematic review and meta-analysis of interventional studies was conducted to compare the efficacy and safety of oral insulin versus subcutaneous (SC) insulin in diabetic patients.
Published on Aug 1, 2015in Therapeutic Delivery
Marlene Lopes6
Estimated H-index: 6
Susana Simões10
Estimated H-index: 10
+ 2 AuthorsAntónio Sousa Ribeiro8
Estimated H-index: 8
Oral insulin able to induce an efficient antihyperglycemic effect either to replace or complement diabetes mellitus therapy is the major goal of health providers, governments and diabetic patients. Oral therapy is associated not only with the desire to exclude needles from the daily routine of diabetic patient but also with the physiological provision of insulin they would get. Despite numerous efforts over the past few decades to develop insulin delivery systems, there is still no commercially ...
Published on Feb 1, 2005in Diabetes Care 15.27
Nick Freemantle72
Estimated H-index: 72
Lawrence Blonde35
Estimated H-index: 35
+ 7 AuthorsE. Stridde3
Estimated H-index: 3
Inhaled insulin (INH, Exubera) is under investigation for preprandial treatment of patients with type 1 and type 2 diabetes (1–3). This dry-powder insulin formulation is delivered by aerosol, permitting the noninvasive administration of rapid-acting insulin (4). Preliminary studies have shown that INH provides reproducible and effective control of glycemia (1,5–7). This randomized controlled trial examined the extent to which the availability of INH affects the perceived acceptability of insulin...
Cited By0